Professional-Track Faculty Positions Available! - Beaverton, Oregon job with Vaccine & Gene Therapy Institute, Oregon Health & Science University

  • 📰 Nature
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 68%

Health Health Headlines News

OVERVIEW The Vaccine & Gene Therapy Institute (VGTI) at Oregon Health & Science University (OHSU) invites applications for professional-track faculty positions at the Assistant, Associate and Full Professor levels.

The Vaccine & Gene Therapy Institute at Oregon Health & Science University invites applications for professional-track faculty positions at the Assistant, Associate and Full Professor levels.

Involvement in an interdisciplinary research or complimentary program in the field of infectious disease. The successful applicant is expected to establish a productive, collaborative, externally-funded research program.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 64. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Gene Therapy’s Promise Meets Nigeria’s Sickle Cell RealityThe U.S. FDA approved a breakthrough treatment for sickle cell anemia. But in Nigeria, social changes could make a bigger difference.
Source: SAPIENS_org - 🏆 227. / 63 Read more »

Gene therapy at CHOP allowed a deaf boy to hear. But some deaf people object to the treatment.A second deaf patient is undergoing the treatment, produced by Eli Lilly, at CHOP on Friday.
Source: PhillyDailyNews - 🏆 89. / 67 Read more »

First-Ever CRISPR-Based Therapy Approved for Sickle Cell DiseaseU.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy.for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder, the treatment, called Casgevy, is the world’s first to genetically tweak cells using theAnother gene therapy for sickle cell disease, called Lyfgenia and developed by biotech company bluebird bio, based in Somerville, Mass., was also approved December 8. Getting a green light for the first CRISPR-based medicine is exciting, says David Altshuler, chief scientific officer at Boston-based Vertex Pharmaceuticals, which developed the drug in a joint venture with CRISPR Therapeutics, a company in Cambridge, Mass. But the fact that the drug fills an unmet need for underserved patients is “more compelling to me, personally, than the fact that it’s CRISPR.” , most of them Black or Latino, have sickle cell disease. It is caused by a genetic defect in hemoglobin, the oxygen-carrying protein in red blood cells
Source: ScienceNews - 🏆 286. / 63 Read more »